

Oregon Health & Science University Hospital and Clinics Provider's Orders



ADULT AMBULATORY INFUSION ORDER
Tezepelumab-ekko (TEZSPIRE)
Injection
Page 1 of 2

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

Weight:kg He	ght:cm
Allergies:	
Diagnosis Code:	
Treatment Start Date:	Patient to follow up with provider on date:

GUIDELINES FOR ORDERING

- 1. Send FACE SHEET and H&P or most recent chart note.
- 2. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with tezepelumab-ekko. Decrease corticosteroids gradually, if appropriate.
- 3. Treat patients with pre-existing helminth infections before therapy with tezepelumab-ekko. If patients become infected while receiving tezepelumab-ekko and do not respond to anti-helminth treatment, discontinue tezepelumab until the parasitic infection resolves.
- 4. Avoid use of live attenuated vaccines.

MEDICATIONS:

tezepelumab-ekko (TEZSPIRE), 210 mg, subcutaneous, ONCE every 4 weeks, for doses.

HYPERSENSITIVITY MEDICATIONS:

- NURSING COMMUNICATION If hypersensitivity or infusion reactions develop, temporarily hold the
 infusion and notify provider immediately. Administer emergency medications per the Treatment
 Algorithm for Acute Infusion Reaction (OHSU HC-PAT-133-GUD, HMC C-132). Refer to algorithm for
 symptom monitoring and continuously assess as grade of severity may progress.
- 2. diphenhydrAMINE (BENADRYL) injection, 25-50 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 3. EPINEPHrine HCI (ADRENALIN) injection, 0.3 mg, intramuscular, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 4. hydrocortisone sodium succinate (SOLU-CORTEF) injection, 100 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction
- 5. famotidine (PEPCID) injection, 20 mg, intravenous, AS NEEDED x 1 dose for hypersensitivity or infusion reaction

^{**}This plan will expire after 365 days at which time a new order will need to be placed**



Oregon Health & Science University Hospital and Clinics Provider's Orders

ADULT AMBULATORY INFUSION ORDER

Health Tezepelumab-ekko (TEZSPIRE) Injection

Page 2 of 2

ACCOUNT NO.
MED. REC. NO.
NAME
BIRTHDATE

Patient Identification

ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.

By signing below, I represent the following: I am responsible for the care of the patient (who is identified at the top of this form); I hold an active, unrestricted license to practice medicine in: Oregon (check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon); My physician license Number is # (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.			
Printed Name:	Phone:	Fax:	
<u>Central Intake:</u> Phone: 971-262-9645 (providers only) Fax: 503 Please check the appropriate box for the pat		ocation:	
□ Beaverton OHSU Knight Cancer Institute 15700 SW Greystone Court Beaverton, OR 97006 Phone number: 971-262-9000 Fax number: 503-346-8058	□ NW Portland Legacy Good Samaritan campus Medical Office Building 3, Suite 150 1130 NW 22nd Ave. Portland, OR 97210 Phone number: 971-262-9600 Fax number: 503-346-8058		
☐ Gresham Legacy Mount Hood campus Medical Office Building 3, Suite 140 24988 SE Stark Gresham, OR 97030 Phone number: 971-262-9500 Fax number: 503-346-8058	Medical Office 19260 SW 65tl Tualatin, OR 9	7062 <mark>: 971-262-9700</mark>	

Infusion orders located at: www.ohsuknight.com/infusionorders